BICARA THERAPEUTICS INC

BCAXNASDAQ

🏆 #1564 by market capEarnings Aug 11 · PreUS Equity

$614.29▲ $45.70 (+7.44%)

Simulated price

1h—

24h▲ 7.4%

7d—

14d—

30d—

1y—

🏦Market Cap

$1.82B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for BCAX.

Trading Snapshot

Day Range: $607.81 – $619.64
52-Week Range: $9.57 – $30.99
Volume: $2.24B
Avg Volume: $1.57B
Shares Outstanding: 65.7M
Next Earnings: Sep 13, 2026

Fundamentals Snapshot

Annual Revenue: $179M
Last Q Revenue: $44M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.77
Dividend Yield: —

Why Investors Own BCAX

✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
✓Healthy economics — 68% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$179M▲ +10.6% YoY

Gross Margin (TTM)

68.1%▲ +3.5% YoY

Operating Income (TTM)

$48M▲ +10.6% YoY

Free Cash Flow (TTM)

$31M▲ +10.6% YoY

About BICARA THERAPEUTICS INC

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

🦦